Article Text

PDF

Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy
  1. S R Vavricka1,
  2. T Wettstein1,
  3. R Speich1,
  4. A Gaspert2,
  5. E B Bachli1
  1. 1Department of Medicine, University of Zurich, Switzerland
  2. 2Department of Pathology, University of Zurich, Switzerland
  1. Correspondence to:
    Dr E B Bachli, Department of Medicine, University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland;
    esther.baechli{at}dim.usz.ch

Abstract

Tumour necrosis factor α (TNFα) antagonists are an established therapeutic option in Crohn's disease and rheumatoid arthritis. In recently published studies these agents have been used with great success, but little is known about any side effects or long term consequences. They increase the frequency of infections with mycobacteria, where TNFα is thought to be an important host defence factor. We describe one patient who was treated with TNFα antagonists and later developed pulmonary granulomas with caseating necrosis without detection of mycobacteria or any other pathogens. Possible mechanisms involved in this newly recognised side effect are discussed.

  • pulmonary granulomas
  • tumour necrosis factor α antagonist

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.